Publicité
Publicité

TOI

TOI logo

The Oncology Institute, Inc. Common Stock

4.19
USD
Sponsorisé
-0.12
-2.74%
09 janv., 15:59 UTC -5
Fermé
exchange

Après-marché

4.21

+0.02
+0.55%

TOI Rapports sur les bénéfices

Ratio de surprise positive

TOI a dépassé 0 des 10 dernières estimations.

%

Prochain rapport

Date du prochain rapport
23 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
$141.17M
/
-$0.09
Variation implicite de Q3 25 (Revenue/ EPS)
+3.37%
/
-35.71%
Variation implicite de Q4 24 (Revenue/ EPS)
--
/
--

The Oncology Institute, Inc. Common Stock earnings per share and revenue

On 13 nov. 2025, TOI reported earnings of -0.14 USD per share (EPS) for Q3 25, missing the estimate of -0.11 USD, resulting in a -22.27% surprise. Revenue reached 136.56 million, compared to an expected 123.86 million, with a 10.26% difference. The market reacted with a +28.90% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analystes forecast an EPS of -0.09 USD, with revenue projected to reach 141.17 million USD, implying an baisse of -35.71% EPS, and hausse of 3.37% in Revenue from the last quarter.
FAQ
For Q3 2025, The Oncology Institute, Inc. Common Stock reported EPS of -$0.14, missing estimates by -22.27%, and revenue of $136.56M, 10.26% above expectations.
The stock price moved up 28.9%, changed from $3.08 before the earnings release to $3.97 the day after.
The next earning report is scheduled for 23 mars 2026.
Based on 5 analystes, The Oncology Institute, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $141.17M for Q4 2025.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité